Transplant Group, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester General Hospital, UK.
Br J Surg. 2012 Dec;99(12):1665-71. doi: 10.1002/bjs.8956.
Renal ischaemia-reperfusion injury (IRI) is a major cause of acute renal failure and renal transplant dysfunction. The aim of this study was to investigate the efficacy of the endogenous gaseous signalling molecule hydrogen sulphide in protecting against renal IRI.
Large White female pigs underwent laparotomy and cross-clamping of the left renal pedicle for 60 min. Animals were allocated randomly to treatment with either intravenous hydrogen sulphide (n = 6) or saline control (n = 6) 10 min before clamp release, and then underwent a right nephrectomy. Staff were blinded to treatment allocation and animals were recovered for 7 days.
Hydrogen sulphide therapy resulted in a marked reduction in kidney injury with reduced serum creatinine levels on days 1-5, in a reduced area under the creatinine-time curve, and a halving of the time to achieve a creatinine level of less than 250 µmol/l, compared with the control. Hydrogen sulphide also preserved glomerular function, as shown by the urinary protein/creatinine ratio, which, compared with baseline, increased on days 1 and 3 in the control group (mean(s.e.m.) 3·22(1·43), P = 0·016 and 2·59(1·27), P = 0·031), but not in the treatment group (0·99(0·23), P = 0·190 and 1·06(0·44), P = 0·110, respectively). Mean(s.e.m.) tumour necrosis factor α levels at 6 h postreperfusion increased in the control animals (56(6) versus 115(21) pg/ml; P = 0·026), but not in the hydrogen sulphide-treated animals (61(7) versus 74(11) pg/ml; P = 0·460). Renal neutrophil infiltration at 30 min (myeloperoxidase staining) was also significantly reduced by treatment with hydrogen sulphide (P = 0·016).
Hydrogen sulphide offers a promising new approach to ameliorating renal IRI with potential translation into a number of clinical settings, including renal transplantation.
肾缺血再灌注损伤(IRI)是急性肾衰竭和肾移植功能障碍的主要原因。本研究旨在探讨内源性气态信号分子硫化氢在保护肾脏 IRI 中的作用。
大白猪接受剖腹术和左肾蒂夹闭 60 分钟。动物随机分为静脉注射硫化氢(n = 6)或生理盐水对照(n = 6)组,在夹闭前 10 分钟给药,然后行右肾切除术。工作人员对治疗分配情况不知情,动物恢复 7 天。
与对照组相比,硫化氢治疗组血清肌酐水平在第 1-5 天明显降低,肌酐时间曲线下面积降低,达到肌酐水平<250 μmol/l 的时间减半。硫化氢还能维持肾小球功能,尿蛋白/肌酐比值较基线增加,在对照组第 1 天(均值(标准差)3.22(1.43),P = 0.016)和第 3 天(2.59(1.27),P = 0.031),但在治疗组没有增加(0.99(0.23),P = 0.190 和 1.06(0.44),P = 0.110)。再灌注后 6 小时,对照组肿瘤坏死因子α水平升高(56(6)比 115(21)pg/ml;P = 0.026),但治疗组没有升高(61(7)比 74(11)pg/ml;P = 0.460)。用硫化氢治疗还显著减少了 30 分钟时的肾中性粒细胞浸润(髓过氧化物酶染色)(P = 0.016)。
硫化氢为改善肾 IRI 提供了一种很有前景的新方法,可能在包括肾移植在内的许多临床环境中得到应用。